HOME >> BIOLOGY >> NEWS
Novel biotoxin being studied for use in opioid withdrawal

Vancouver-On November 10, 2004 investigators involved in a Phase IIa clinical trial of the novel biotoxin Tetrodotoxin (TTX) for the treatment of opioid withdrawal enrolled their first participants. This double-blind, randomized, cross-over, placebo-controlled trial will evaluate the efficacy and safety of Tetrodin for treatment withdrawal symptoms in 20 opiate-dependent subjects who are receiving methadone in a treatment program. It is the first study involving a biotoxin for opioid withdrawal to be done in North America.

Use of opioids presents many challenges for the addicts, their families, and society as a whole. The health and social consequences include HIV/AIDS, Hepatitis B, and C, tuberculosis, fetal effects, violence, and crime. Family life, workplace, and educational environments are all affected, with associated costs reaching billions of dollars each year.

"There's a need for new treatments for heroin dependence and for opiate abuse, and this is one potential new approach, directed at modifying the physical dependence that occurs with repeated use of drugs like heroin," said Dr. Edward Sellers President and CEO of Ventana Clinical Research Corporation. Dr. Sellers is the lead investigator on the study, and is a member of numerous national and international editorial boards, governmental advisory committees, and international organizations including the World Health Organization Expert Advisory Committee on Drug Dependence.

What is Opioid Dependence - Why use a Biotoxin?

Opioid dependence is generally characterized by a withdrawal syndrome that occurs when the drug is abruptly discontinued. Managing withdrawal is essential in enabling people to begin treatment programs to end their opioid dependence. The traditional medical management of opioid withdrawal involves substituting long-acting opioids for shorter-acting opioids, and gradually tapering the treatment.

However, unlike traditional therapies Tetr
'"/>

Contact: Don Evans
don@wexpharma.com
604-676-7894
WEX Pharmaceuticals Inc.
18-Nov-2004


Page: 1 2

Related biology news :

1. Novel sugar-to-hydrogen technology promises transportation fuel independence
2. Novel system developed to turn data into real-time, interactive 3-D images
3. Novel strategies for healthy aging
4. Novel salamander robot crawls its way up the evolutionary ladder
5. Novel test identifies lymphoma patients likely to respond to new therapy
6. Novel laboratory technique nudges genes into activity
7. Novel approaches to tackling obesity, cancer and MRSA
8. Novel approach to cancer drug given major boost
9. Novel regulation of the common tumor suppressor PTEN
10. Novel EGFR ectodomain mutations in glioblastoma
11. Novel regulatory mechanism identified for key tumor suppressor p53

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/19/2019)... YORK (PRWEB) , ... November 19, 2019 , ... The ... Plaza Times Square in New York City. The one-day event will be chaired by ... group of leaders in the space. , “We are witnessing significant innovation in ...
(Date:11/14/2019)... ... November 13, 2019 , ... NDA Partners Chairman ... regulatory affairs and program management executive with more than 33 years of regulatory ... the firm as an Expert Consultant. , Robert Peterson has extensive experience ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... medical devices, today announced the creation of a Global Regulatory Affairs Department, to ... Device industry is that the regulatory element to any Medtech organization is more ...
Breaking Biology News(10 mins):
(Date:12/2/2019)... ... ... Registration is now open for the American Society of Gene & Cell ... May 12-15, 2020, in Boston. The meeting is the premier event in the field ... stakeholders with the goal of advancing gene and cell therapies to alleviate human disease. ...
(Date:11/20/2019)... ... November 20, 2019 , ... ... of about 8,500 microturbine electrical power generation units from 2019-2028. The value of ... over 2017's projection of 3,821 units worth $569 million. , Reference to ...
(Date:11/12/2019)... Wis. (PRWEB) , ... November 12, 2019 , ... ... food ingredient solutions for the food and beverage industry launched a new innovative ... improve the digital experience. Now, the website offers global visitors updated ingredient usage ...
(Date:11/6/2019)... ... ... Diversified Technologies, Inc. has introduced a PEF production system for ... processing. , The DTI Industrial PEF Unit can pre-treat whole pieces of fruits and ... up to 50% and achieve up to an 80% reduction of drying energy. ...
Breaking Biology Technology:
Cached News: